The cannabis trade saw another competitor assume the spotlight Monday, with word that Oceanside, Calif.-based Therapeutics Solutions International, Inc. (OTC:TSOI) had forged a sales agreement for the exclusive distribution of NanoStilbene and Nano Cannabidiol throughout Mexico with Immun ET.
TSOI recently announced preliminary data for immune stimulation in advanced cancer patients with NanoStilbene, a nanoemulsion of nanoparticle pterostilbene that is taken orally. Daily treatment with NanoStilbene caused a reduction in serum levels of a variety of inflammatory markers.
The results suggest that NanoStilbene may aid in the immunotherapy of cancer-rescuing T cell and NK cell activities.
Said CEO Tim Dixon, "Having worked closely with … Immun ET for many years in advanced cancer studies where in 2015 we conducted our 10 patient StemVacs immunotherapy clinical trial, we are excited to continue our long-standing relationship further solidified by this award announced today."
Shares in TSOI leaped 24.3% to 42/100ths of a cent Monday, on 610,000 shares.
